Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease

Canadian Journal of Psychiatry

Volumn 52, Issue 10, 2007, Pages 630-646

  Herrmann, Nathan ^a,b   Lanctôt, Krista L ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; CITALOPRAM; CLOMIPRAMINE; DONEPEZIL; ESTROGEN; FLUOXETINE; GALANTAMINE; HALOPERIDOL; IMIPRAMINE; MEMANTINE; MOCLOBEMIDE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; PROPRANOLOL; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SERTRALINE; TRAZODONE; UNINDEXED DRUG; VALPROIC ACID;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; BEHAVIOR THERAPY; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; EMBASE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MEDLINE; META ANALYSIS; MORTALITY; MUSIC THERAPY; PHOTOTHERAPY; PSYCHOSIS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SOCIALIZATION; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

EID: 36048995913     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674370705201004     Document Type: Review

References (156)

1. Finkel SI, Costa e Silva J, Cohen G, et al. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr. 1996;8(Suppl 3):497-500.
2. Teri L, Rabins P, Whitehouse P, Berg L, et al. Management of behavior disturbance in Alzheimer disease: current knowledge and future directions. Alzheimer Dis Assoc Disord. 1992;6:77-88.
3. Rosenblatt A, Samus QM, Steele CD, et al. The Maryland Assisted Living Study: prevalence, recognition, and treatment of dementia and other psychiatric disorders in the assisted living population of central Maryland. J Am Geriatr Soc. 2004;52:1618-1625.
4. Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157:708-714.
5. Miller TP, Tinklenberg JR, Brooks JO 3rd, et al. Selected psychiatric symptoms associated with rate of cognitive decline in patients with Alzheimer's disease. J Geriatr Psychiatry Neurol. 1993;6:235-238.
6. Moritz DJ, Fox PJ, Luscombe FA, et al. Neurological and psychiatric predictors of mortality in patients with Alzheimer disease in California. Arch Neurol. 1997;54:878-885.
7. Walsh JS, Welch HG, Larson EB. Survival of outpatients with Alzheimer-type dementia. Ann Intern Med. 1990;113:429-434.
8. Lopez OL, Wisniewski SR, Becker JT, et al. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol. 1999;56:1266-1272.
9. Mortimer JA, Ebbitt B, Jun SP, et al. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology. 1992;42:1689-1696.
10. Ryden MB. Aggressive behavior in persons with dementia who live in the community. Alzheimer Dis Assoc Disord. 1988;2:342-355.
11. Chenoweth B, Spencer B. Dementia: the experience of family caregivers. Gerontologist. 1986;26:267-272.
12. Clyburn LD, Stones MJ, Hadjistavropoulos T, et al. Predicting caregiver burden and depression in Alzheimer's disease. J Gerontol B Psychol Sci Soc Sci. 2000;55:S2-S13.
13. Coen RF, Swanwick GR, O'Boyle CA, et al. Behaviour disturbance and other predictors of carer burden in Alzheimer's disease. Int J Geriatr Psychiatry. 1997;12:331-336.
14. Donaldson C, Tarrier N, Burns A. Determinants of carer stress in Alzheimer's disease. Int J Geriatr Psychiatry. 1998;13:248-256.
15. Beeri MS, Werner P, Davidson M, et al. The cost of behavioral and psychological symptoms of dementia (BPSDS) in community dwelling Alzheimer's disease patients. Int J Geriatr Psychiatry. 2002;17:403-408.
16. Herrmann N, Lanctôt KL, Sambrook R, et al. The contribution of neuropsychiatric symptoms to the cost of dementia care. Int J Geriatr Psychiatry. 2006;21:972-976.
17. Cohen-Mansfield J, Mintzer JE. Time for change: the role of nonpharmacological interventions in treating behavior problems in nursing home residents with dementia. Alzheimer Dis Assoc Disord. 2005;19:37-40.
18. Lanctôt KL, Herrmann N, Mazzotta P. Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci. 2001;13:5-21.
19. Herrmann N, Lanctôt KL, Khan LR. The role of norepinephrine in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci. 2004;16:261-276.
20. Sweet RA, Pollock BG, Mulsant BH, et al. Association of plasma homovanillic acid with behavioral symptoms in patients diagnosed with dementia: a preliminary report. Biol Psychiatry. 1997;42:1016-1023.
21. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry. 2000;157:4-15.
22. Lanctôt KL, Herrmann N, Mazzotta P, et al. GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can J Psychiatry. 2004;49:439-453.
23. Kiely DK, Morris JN, Algase DL. Resident characteristics associated with wandering in nursing homes. Int J Geriatr Psychiatry. 2000;15:1013-1020.
24. Cohen-Mansfield J, Billig N, Lipson S, et al. Medical correlates of agitation in nursing home residents. Gerontology. 1990;36:150-158.
25. Learoyd BM. Psychotropic drugs and the elderly patient. Med J Aust. 1972;1:1131-1133.
26. Lanctôt KL, Bowles SK, Herrmann N, et al. Drugs mimicking dementia. Dementia symptoms associated with psychotropic drugs in institutionalised cognitively impaired patients. CNS Drugs. 2000;14:381-390.
27. Corbin SL, Eastwood MR. Sensory deficits and mental disorders of old age: causal or coincidental associations? Psychol Med. 1986;16:251-256.
28. Horowitz A. The relationship between vision impairment and the assessment of disruptive behaviors among nursing home residents. Gerontologist. 1997;37:620-628.
29. Chapman FM, Dickinson J, McKeith I, et al. Association among visual hallucinations, visual acuity, and specific eye pathologies in Alzheimer's disease: treatment implications. Am J Psychiatry. 1999;156:1983-1985.
30. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308-2314.
31. Cohen-Mansfield J, Billig N. Agitated behaviors in the elderly. I. A conceptual review. J Am Geriatr Soc. 1986;34:711-721.
32. Alexopoulos GS, Abrams RC, Young RC, et al. Cornell Scale for Depression in Dementia. Biol Psychiatry. 1988;23:271-284.
33. Yudofsky SC, Silver JM, Jackson W, et al. The Overt Aggression Scale for the objective rating of verbal and physical aggression. Am J Psychiatry. 1986;143:35-39.
34. Nilsson K, Palmstierna T, Wistedt B. Aggressive behavior in hospitalized psychogeriatric patients. Acta Psychiatr Scand. 1988;78:172-175.
35. The Committee on Safety of Medicines. New advice issued about risperidone and olanzapine [Internet]. CSM; 2004 Mar 9 [cited 2007 Jul]. Available from: http://www.mhra.gov.uk/home.
36. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry. 2001;9:361-381.
37. Snowden M, Sato K, Roy-Byrne P. Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature. J Am Geriatr Soc. 2003;51:1305-1317.
38. Opie J, Rosewarne R, O'Connor DW. The efficacy of psychosocial approaches to behaviour disorders in dementia: a systematic literature review. Aust N Z J Psychiatry. 1999;33:789-799.
39. Livingston G, Johnston K, Katona C, et al. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry. 2005;162:1996-2021.
40. Verkaik R, van Weert JC, Francke AL. The effects of psychosocial methods on depressed, aggressive and apathetic behaviors of people with dementia: a systematic review. Int J Geriatr Psychiatry. 2005;20:301-314.
41. Thorgrimsen L, Spector A, Wiles A, et al. Aroma therapy for dementia. Cochrane Database Syst Rev. 2003;CD003150.
42. Forbes D, Morgan DG, Bangma J, et al. Light therapy for managing sleep, behaviour, and mood disturbances in dementia. Cochrane Database Syst Rev. 2005;2:CD003946.
43. Vink AC, Birks JS, Bruinsma MS, et al. Music therapy for people with dementia. Cochrane Database Syst Rev. 2005;CD003477.
44. Liperoti R, Mor V, Lapane KL, et al. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry. 2003;64:1106-1112.
45. Semla TP, Palla K, Poddig B, et al. Effect of the Omnibus Reconciliation Act 1987 on antipsychotic prescribing in nursing home residents. J Am Geriatr Soc. 1994;42:648-652.
46. Beers MH, Ouslander JG, Rollingher I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med. 1991;151:1825-1832.
47. American Geriatrics Society and American Association for Geriatric Psychiatry. Consensus statement on improving the quality of mental health care in US nursing homes: management of depression and behavioral symptoms associated with dementia. J Am Geriatr Soc. 2003;51:1287-1298.
48. Cohen-Mansfield J, Lipson S, Werner P, et al. Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study. Arch Intern Med. 1999;159:1733-1740.
49. van Reekum R, Clarke D, Conn D, et al. A randomized, placebo-controlled trial of the discontinuation of long-term antipsychotics in dementia. Int Psychogeriatr. 2002;14:197-210.
50. Ballard CG, Thomas A, Fossey J, et al. A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psychiatry. 2004;65:114-119.
51. Ruths S, Straand J, Nygaard HA, et al. Effect of antipsychotic withdrawal on behavior and sleep/wake activity in nursing home residents with dementia: a randomized, placebo-controlled, double-blinded study. The Bergen District Nursing Home Study. J Am Geriatr Soc. 2004;52:1737-1743.
52. Alexopoulos GS, Silver JM, Kahn DA, et al. The expert consensus guideline series: treatment of agitation in older persons with dementia. Postgrad Med. 1998;26:1-88.
53. Herrmann N. Recommendations for the management of behavioral and psychological symptoms of dementia. Can J Neurol Sci. 2001;28 Suppl 1:S96-107.
54. Alexopoulos GS, Streim J, Carpenter D, et al.. Using antipsychotic agents in older patients. J Clin Psychiatry. 2004;65(Suppl 2):5-99. Discussion 100-102;quiz 103-104.
55. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293:596-608.
56. Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc. 1990;38:553-563.
57. Lanctôt KL, Best TS, Mittmann N, et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry. 1998;59:550-561. Quiz 562-553.
58. Rapoport M, Mamdani M, Shulman KI, et al. Antipsychotic use in the elderly: shifting trends and increasing costs. Int J Geriatr Psychiatry. 2005;20:749-753.
59. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: metaanalysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:191-210.
60. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355:1525-1538.
61. Zhong K, Tariot PN, Mintzer J, et al. Quetiapine to treat agitation in dementia: a randomized, double-blind placebo-controlled trial. Curr Alzheimer Res. 2007;4:81-93.
62. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ. 2002;167:1269-1270.
63. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ. 2004;170:1395.
64. Health Canada. Health Canada endorsed important safety information on atypical antipsychotic drugs and dementia [Internet]. 2005 Jun 22 [cited 2005 Dec 12]. Available from: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/ prof/atyp-antipsycho_hpc_e.html.
65. Herrmann N, Lanctôt KL. Do atypical antipsychotics cause stroke? CNS Drugs. 2005;19:91-103.
66. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: metaanalysis of randomized placebo-controlled trials. JAMA. 2005;294:1934-1943.
67. Liperoti R, Gambassi G, Lapane KL, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry. 2005;66:1090-1096.
68. Layton D, Harris S, Wilton LV, et al. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. J Psychopharmacol. 2005;19:473-482.
69. Herrmann N, Mamdani M, Lanctôt KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry. 2004;161:1113-1115.
70. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ. 2005;330:445.
71. Raivio MM, Laurila JV, Strandberg TE, et al. Psychotropic medication and stroke outcome [letter]. Am J Psychiatry. 2005;162:1027. Reply 1027-1028.
72. Nasrallah HA, White T, Nasrallah AT. Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol: preliminary analysis of retrospective data. Am J Geriatr Psychiatry. 2004;12:437-439.
73. Suh GH, Shah A. Effect of antipsychotics on mortality in elderly patients with dementia: a 1-year prospective study in a nursing home. Int Psychogeriatr. 2005;17:429-441.
74. Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176:627-632.
75. Herrmann N, Lanctôt KL. Atypical antipsychotics for neuropsychiatric symptoms of dementia: malignant or maligned? Drug Saf. 2006;29:833-843.
76. Trinh NH, Hoblyn J, Mohanty S, et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a metaanalysis. JAMA. 2003;289:210-216.
77. Mega MS, Masterman DM, O'Connor SM, et al. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol. 1999;56:1388-1393.
78. Herrmann N, Rabheru K, Wang J, et al. Galantamine treatment of problematic behavior in alzheimer disease: post-hoc analysis of pooled data from three large trials. Am J Geriatr Psychiatry. 2005;13:527-534.
79. Cummings JL, McRae T, Zhang R. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry. 2006;14:605-612.
80. Cummings JL, Schneider L, Tariot PN, et al. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry. 2004;161:532-538.
81. Edwards K, Koumaras B, Chen M, et al. Long-term effects of rivastigmine treatment on the need for psychotropic medications in nursing home patients with Alzheimer's disease. Clin Drug Invest. 2005;25:507-515.
82. Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology. 2004;63:214-219.
83. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333-1341.
84. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317-324.
85. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999;14:135-146.
86. Gauthier S, Wirth Y, Mobius HJ. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry. 2005;20:459-464.
87. Cummings JL, Schneider E, Tariot PN, et al. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 2006;67:57-63.
88. Olin JT, Schneider LS, Katz IR, et al. Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry. 2002;10:125-128.
89. Thompson S, Herrmann N, Rapoport MJ, et al. Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a metaanalysis. Can J Psychiatry. 2007;52:248-255.
90. Sultzer DL, Gray KF, Gunay I, et al. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry. 1997;5:60-69.
91. Teri L, Logsdon RG, Peskind E, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000;55:1271-1278.
92. Lawlor BA, Radcliffe J, Molchan SE, et al. A pilot placebo-controlled study of trazodone and buspirone in Alzheimer's disease. Int J Geriatr Psychiatry. 1994;9:55-59.
93. Martinon-Torres G, Fioravanti M, Grimley EJ. Trazodone for agitation in dementia. The Cochrane Database of Systematic Reviews. 2004;CD004990:
94. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry. 1990;157:894-901.
95. Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry. 2002;159:460-465.
96. Lanctôt KL, Herrmann N, van Reekum R, et al. Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. Int J Geriatr Psychiatry. 2002;17:531-541.
97. Tariot PN, Erb R, Leibovici A, et al. Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study. J Am Geriatr Soc. 1994;42:1160-1166.
98. Cooney C, Mortimer A, Smith A, et al. Carbamazepine use in aggressive behaviour associated with senile dementia. Int J Geriatr Psychiatry. 1996;11:901-905.
99. Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998;155:54-61.
100. Olin JT, Fox LS, Pawluczyk S, et al. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry. 2001;9:400-405.
101. Porsteinsson AP, Tariot PN, Erb R, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry. 2001;9:58-66.
102. Sival RC, Haffmans PM, Jansen PA, et al. Sodium valproate in the treatment of aggressive behavior in patients with dementia - a randomized placebo controlled clinical trial. Int J Geriatr Psychiatry. 2002;17:579-585.
103. Tariot PN, Schneider LS, Mintzer JE, et al. Safety and tolerability of divalproex sodium in treatment of signs and symptoms of mania in elderly patients with dementia: results of a double-blind placebo-controlled trial. Curr Ther Res Clin Exp. 2001;62:51-67.
104. Tariot PN, Raman R, Jakimovich L, et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry. 2005;13:942-949.
105. Herrmann N, Lanctôt KL, Rothenburg LS, et al. A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dement Geriatr Cogn Disord. 2007;23:116-119.
106. So CC, Wong KF. Valproate-associated dysmyelopoiesis in elderly patients. Am J Clin Pathol. 2002;118:225-228.
107. Trannel TJ, Ahmed I, Goebert D. Occurrence of thrombocytopenia in psychiatric patients taking valproate. Am J Psychiatry. 2001;158:128-130.
108. Lonergan ET, Luxenberg J. Valproate preparations for agitation in dementia. The Cochrane Database of Systematic Reviews. 2005;3.
109. Herrmann N, Lanctôt K, Myszak M. Effectiveness of gabapentin for the treatment of behavioral disorders in dementia. J Clin Psychopharmacol. 2000;20:90-93.
110. Moretti R, Torre P, Antonello RM, et al. Gabapentin for the treatment of behavioural alterations in dementia: preliminary 15-month investigation. Drugs Aging. 2003;20:1035-1040.
111. Fhager B, Meiri IM, Sjogren M, et al. Treatment of aggressive behavior in dementia with the anticonvulsant topiramate: a retrospective pilot study. Int Psychogeriatr. 2003;15:307-309.
112. Tekin S, Aykut-Bingol C, Tanridag T, et al. Antiglutamatergic therapy in Alzheimer's disease - effects of lamotrigine. Short communication. J Neural Transm. 1998;105:295-303.
113. Devarajan S, Dursun SM. Aggression in dementia with lamotrigine treatment. Am J Psychiatry. 2000;157:1178.
114. De Leon OA. Treatment of psychotic symptoms with lamotrigine in Alzheimer disease. J Clin Psychopharmacol. 2004;24:232-233.
115. Beber CR. Management of behavior in the institutionalized aged. Dis Nerv Syst. 1965;26:591-595.
116. Chesrow EJ, Kaplitz SE, Vetra H, et al. Blind study of oxazepam in the management of geriatric patients with behavioral problems. Clin Med. 1965;71:1001-1005.
117. Sanders JF. Evaluation of Oxazepam and Placebo in Emotionally Disturbed Aged Patients. Geriatrics. 1965;20:739-746.
118. Kirven LE, Montero EF. Comparison of thioridazine and diazepam in the control of nonpsychotic symptoms associated with senility: double-blind study. J Am Geriatr Soc. 1973;21:546-551.
119. Covington JS. Alleviating agitation, apprehension, and related symptoms in geriatric patients: a double-blind comparison of a phenothiazine and a benzodiazepien. South Med J. 1975;68:719-724.
120. Stotskey B. Multicenter study comparing thioidazine with diazepam and placebo in elderly nonpsychotic patients with emotional and behavioral disorders. Clin Ther. 1984;6:546-549.
121. Coccaro EF, Kramer E, Zemishlany Z, et al. Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients. Am J Psychiatry. 1990;147:1640-1645.
122. Ancill RJ, Carlyle WW, Liang RA, et al. Agitation in the demented elderly: a role for benzodiazepines? Int Clin Psychopharmacol. 1991;6:141-146.
123. Christensen DB, Benfield WR. Alprazolam as an alternative to low-dose haloperidol in older, cognitively impaired nursing facility patients. J Am Geriatr Soc. 1998;46:620-625.
124. Sunderland T, Weingartner H, Cohen RM, et al. Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls. Psychopharmacology (Berl). 1989;99:129-133.
125. Glass J, Lanctôt KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: metaanalysis of risks and benefits. BMJ 2005;331:1169.
126. Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002;26:494-504.
127. Greendyke RM, Kanter DR, Schuster DB, et al. Propranolol treatment of assaultive patients with organic brain disease. A double-blind crossover, placebo-controlled study. J Nerv Ment Dis. 1986;174:290-294.
128. Greendyke RM, Kanter DR. Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double-blind study. J Clin Psychiatry. 1986;47:423-426.
129. Herrmann N, Lanctôt KL, Eryavec G, et al. Noradrenergic activity is associated with response to pindolol in aggressive Alzheimer's disease patients. J Psychopharmacol. 2004;18:215-220.
130. Peskind ER, Tsuang DW, Bonner LT, et al. Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study. Alzheimer Dis Assoc Disord. 2005;19:23-28.
131. Cantillon M, Brunswick R, Molina D, et al. Buspirone vs. haloperidol. A double-blind trial for agitation in nursing home population with Alzheimer 's disease. Am J Geriatr Psychiatry. 1996;4:263-267.
132. Kyomen HH, Hennen J, Gottlieb GL, et al. Estrogen therapy and noncognitive psychiatric signs and symptoms in elderly patients with dementia. Am J Psychiatry. 2002;159:1225-1227.
133. Kyomen HH, Satlin A, Hennen J, et al. Estrogen therapy and aggressive behavior in elderly patients with moderate-to-severe dementia: results from a short-term, randomized, double-blind trial. Am J Geriatr Psychiatry. 1999;7:339-348.
134. Hall KA, Keks NA, O'Connor DW. Transdermal estrogen patches for aggressive behavior in male patients with dementia: a randomized, controlled trial. Int Psychogeriatr. 2005;17:165-178.
135. Volicer L, Stelly M, Morris J, et al. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 1997;12:913-919.
136. Serfaty M, Kennell-Webb S, Warner J, et al. Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. Int J Geriatr Psychiatry. 2002;17:1120-1127.
137. Singer C, Tractenberg RE, Kaye J, et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep. 2003;26:893-901.
138. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999;60:107-115.
139. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53:946-955.
140. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry. 2000;57:968-976.
141. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003;64:134-143.
142. De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2004;19:115-126.
143. Deberdt WG, Dysken MW, Rappaport SA, et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry. 2005;13:722-730.
144. Ballard C, Margallo-Lana M, Juszczak E, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ. 2005;330:874.
145. De Deyn P, Jeste DV, Swanink R, et al. Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. J Clin Psychopharmacol. 2005;25:463-467.
146. Tariot PN, Schneider L, Katz IR, et al. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry. 2006;14:767-776.
147. Zhong KX, Tariot PN, Mintzer J, et al. Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. Curr Alzheimer Res. 2007;4:81-93.
148. Reifler BV, Teri L, Raskind M, et al. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am J Psychiatry. 1989;146:45-49.
149. Petracca G, Teson A, Chemerinski E, et al. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 1996;8:270-275.
150. Magai C, Kennedy G, Cohen CI, et al. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease. Am J Geriatr Psychiatry. 2000;8:66-74.
151. Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr. 2001;13:233-240.
152. Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003;60:737-746.
153. Roth M, Mountjoy CQ, Amrein R. Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. Br J Psychiatry. 1996;168:149-157. 154. Auchus AP, Bissey-Black C. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 1997;9:591-593.
154. Finkel SI, Mintzer JE, Dysken M, et al. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. Int J Geriatr Psychiatry. 2004;19:9-18.
155. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc. 2001;49:1590-1599.
156. Asayama K, Yamadera H, Ito T, et al. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J Nippon Med Sch. 2003;70:334-341.